Axa boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,321 shares of the biotechnology company’s stock after buying an additional 3,692 shares during the quarter. Axa’s holdings in United Therapeutics were worth $10,404,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in United Therapeutics by 4.2% during the third quarter. SG Americas Securities LLC now owns 10,799 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 436 shares during the period. Pacer Advisors Inc. grew its position in United Therapeutics by 6.9% during the third quarter. Pacer Advisors Inc. now owns 7,188 shares of the biotechnology company’s stock valued at $842,000 after buying an additional 461 shares during the period. Amalgamated Bank grew its position in United Therapeutics by 6.0% during the fourth quarter. Amalgamated Bank now owns 8,685 shares of the biotechnology company’s stock valued at $1,285,000 after buying an additional 489 shares during the period. American International Group Inc. boosted its position in United Therapeutics by 0.6% during the fourth quarter. American International Group Inc. now owns 91,580 shares of the biotechnology company’s stock worth $13,549,000 after purchasing an additional 524 shares during the period. Finally, American Century Companies Inc. boosted its position in United Therapeutics by 3.7% during the third quarter. American Century Companies Inc. now owns 15,779 shares of the biotechnology company’s stock worth $1,849,000 after purchasing an additional 567 shares during the period. Institutional investors own 99.85% of the company’s stock.
UTHR has been the subject of a number of research reports. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Wedbush reiterated an “outperform” rating and set a $232.00 target price (up previously from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. Finally, Oppenheimer increased their target price on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research report on Friday, January 5th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. United Therapeutics has an average rating of “Hold” and an average price target of $135.20.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. The business had revenue of $464.70 million for the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. United Therapeutics’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the firm posted $4.12 earnings per share. equities analysts anticipate that United Therapeutics Co. will post 12.46 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/12/axa-boosts-position-in-united-therapeutics-co-uthr.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.